Merck & Co Inc (NYSE:MRK)
| 110.75 Delayed Data As of Jun 09 |  +0.43 / +0.39%Today’s Change | 83.05 Today|||52-Week Range 119.65 | -0.18% Year-to-Date |
MRK Regular Dividend: MRK will begin trading ex-dividend on 06/14/23 with a $0.73 dividend payable to shareholders of record as of 06/15/23.
Latest MRK News | Press Releases
Today’s Trading
| Previous close | 110.32 |
| Today’s open | 110.04 |
| Day’s range | 109.09 - 111.50 |
| Volume | 6,522,058 |
| Average volume (3 months) | 7,673,193 |
| Market cap | $285.5B |
Data as of 4:00pm ET, 06/09/2023
Growth & Valuation
| Earnings growth (last year) | +11.18% |
| Earnings growth (this year) | -6.64% |
| Earnings growth (next 5 years) | +8.80% |
| Revenue growth (last year) | +19.56% |
| P/E ratio | 21.6 |
| Price/Sales | 4.82 |
| Price/Book | 6.21 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| NVONovo Nordisk | -1.38 | -0.87% |
| ABBVAbbVie | +0.50 | +0.36% |
| AZNAstraZeneca | -0.19 | -0.26% |
| PFEPfizer | -0.12 | -0.31% |
Data as of 4:00pm ET, 06/09/2023
Financials
| Next reporting date | August 1, 2023 |
| EPS forecast (this quarter) | $1.85 |
| Annual revenue (last year) | $58.5B |
| Annual profit (last year) | $14.5B |
| Net profit margin | 24.83% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Kenilworth, New Jersey |
Forecasts
